DuPont de Nemours, Inc. (DD)
DuPont Expands Sugar Separation Expertise With New Digital Tool
DD launches a digital tool using chromatography data to help sugar and sweetener makers assess separation options and identify resins.
DuPont: Secular Growth And Margin Expansion Should Drive Good Upside
DuPont is rated Buy, offering secular growth and margin expansion at an attractive valuation, with strong exposure to healthcare, water, EV, and aerospace markets. Healthcare and Water Technologies drive structural growth, supported by leading positions in medical devices and semiconductor water treatment, with resilient recurring revenues. The Diversified Industrials segment benefits from EV battery adhesives and aerospace, with growth initiatives and margin expansion through 80/20 simplification and productivity programs.
Here's Why You Should Hold DuPont Stock in Your Portfolio for Now
DD's innovation, acquisitions and productivity gains support growth, but uneven construction demand and higher input costs weigh on margins.
DuPont Expands Tyvek Portfolio With Lower-Carbon Material Innovation
DD expands Tyvek with Renewable Attribution globally, helping C&I customers cut product carbon footprints without redesigning processes.
DD's MemCor MBR System Chosen for Major Plant Upgrade in Australia
DuPont's MemCor MBR system will add about 97 million liters per day of treatment capacity in Canberra as wastewater demand rises with population growth.
DD Q2 Earnings Call Points to Faster Second-Half Growth
DuPont raises its 2026 outlook as pricing, productivity and key end markets point to faster second-half growth.
DuPont de Nemours Q2 Earnings Call Highlights
DuPont de Nemours NYSE: DD raised its full-year 2026 outlook after reporting second-quarter results that exceeded its prior guidance, supported by organic growth, productivity gains and cash-flow generation.
DD's Q2 Earnings Beat on Higher Organic Sales, Revenues Up Y/Y
DuPont topped Q2 earnings and sales estimates, boosted by healthcare, industrial water and aerospace demand, then raised its full-year 2026 outlook.
DuPont de Nemours (DD) Reports Q2 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for DuPont de Nemours (DD) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
DuPont to Report Q2 Earnings: What's in the Offing for the Stock?
DD is expected to have benefited from its innovation-driven investment, productivity actions and acquisitions amid cost pressures in Q2.
DuPont: Macro Pressures Persist, Q3 Guidance Could Be Weak (Rating Downgrade)
DuPont remains undervalued, but I move from Strong Buy to Buy due to Q3 guidance concerns and currency headwinds. Q2 is expected to deliver a small beat, driven by strong healthcare and aerospace, though construction market softness persists in Diversified Industrials. DD's recent $275M accelerated share repurchase signals management's conviction in undervaluation, supported by robust EPS growth and margin expansion.
DuPont Achieves Renewable Power Milestone in US Healthcare Sites
DuPont's U.S. healthcare manufacturing sites now run on renewable electricity, advancing climate goals and lowering emissions.
